<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">101280339</journal-id>
<journal-id journal-id-type="pubmed-jr-id">33033</journal-id>
<journal-id journal-id-type="nlm-ta">Transl Res</journal-id>
<journal-id journal-id-type="iso-abbrev">Transl Res</journal-id>
<journal-title-group>
<journal-title>Translational research : the journal of laboratory and clinical medicine</journal-title>
</journal-title-group>
<issn pub-type="ppub">1931-5244</issn>
<issn pub-type="epub">1878-1810</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">27519147</article-id>
<article-id pub-id-type="pmc">5164971</article-id>
<article-id pub-id-type="doi">10.1016/j.trsl.2016.07.016</article-id>
<article-id pub-id-type="manuscript">NIHMS806324</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The influence of gut derived CD39 regulatory T cells in CNS demyelinating disease</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Ochoa-Repáraz</surname>
<given-names>Javier</given-names>
</name>
<degrees>Ph.D</degrees>
<xref ref-type="author-notes" rid="FN1">*</xref>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kasper</surname>
<given-names>Lloyd H.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>Department of Biology, Eastern Washington University, Cheney, WA 99004</aff>
<aff id="A2"><label>2</label>Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Hanover, NH 03755</aff>
<author-notes>
<corresp id="FN1"><label>*</label>Corresponding author: Department of Biology, SCI 289, Cheney WA 99004, <email>jochoareparaz@ewu.edu</email>, Phone: (509) 359-2348, Fax: (509) 359-6867</corresp>
<fn id="FN2">
<p>Department of Microbiology and Immunology, Remsen Building, Room 132A, Geisel School of Medicine at Dartmouth College, Hanover NH 03755, <email>Lloyd.h.kasper@dartmouth.edu</email>, Phone: (603) 653-9909</p>
</fn>
<fn fn-type="COI-statement" id="FN3">
<p>
<bold>Conflict of Interest:</bold>
</p>
<p>All authors have read the journal’s policy on conflicts of interest. Javier Ochoa-Repáraz Ph.D, reports grants from Genzyme, personal remuneration from Symbiotix Biotherapies, during the conduct of the study. Dr. Lloyd H Kasper MD, reports grants from Genzyme, Teva and Symbiotix Biotherapies, personal remuneration from TEVA Neuroscience and Genzyme that are outside the submitted work.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>5</day>
<month>8</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="epub">
<day>28</day>
<month>7</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="ppub">
<month>1</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>1</month>
<year>2018</year>
</pub-date>
<volume>179</volume>
<fpage>126</fpage>
<lpage>138</lpage>
<!--elocation-id from pubmed: 10.1016/j.trsl.2016.07.016-->
<abstract>
<p id="P2">There is considerable interest in trying to understand the importance of the gut microbiome in human diseases. The association between dysbiosis, an altered microbial composition, as related to human disease is being explored in the context of different autoimmune conditions, including multiple sclerosis (MS). Recent studies suggest that MS affects the composition of the gut microbiota by altering the relative abundances of specific bacteria and archaea species. Remarkably, some of the bacterial species shown reduced in the gut of MS patients are known to promote immunosuppressive regulatory T cells (Tregs). In MS, the function of a phenotype of Tregs that express CD39, an ectoenzyme involved in the catabolism of ATP as immumomodulatory cells, appears to be reduced. In this review we discuss the involvement of the gut microbiota in the regulation of experimental models of CNS inflammatory demyelination and review the evidence that link the gut microbiome with multiple sclerosis. Further, we hypothesize that the gut microbiome is an essential organ for the control of tolerance in multiple sclerosis patients and a potential source for safer novel therapeutics.</p>
</abstract>
<kwd-group>
<kwd>CD39</kwd>
<kwd>gut microbiota</kwd>
<kwd>dysbiosis</kwd>
<kwd>gut-brain axis</kwd>
<kwd>Multiple Sclerosis</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>